A triple combination cancer immunotherapy based regimen containing adoptive T cell therapy, a PIM kinase inhibitor, and a PD-1 inhibitor could improve survival in a mouse model of melanoma
from Medindia Health News https://ift.tt/2QpNhck
No comments:
Post a Comment